Last reviewed · How we verify
NCT03543566: BAMA
Bladder Antimuscarinic Medication and Accidental Bowel Leakage
trial in Urinary Incontinence, Urge in 32 participants. Completed in 18 January 2019.
18 January 2019
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 32 |
| Start date | 21 May 2018 |
| Primary completion | 18 January 2019 |
| Estimated completion | 18 January 2019 |
| Sites | 1 location across United States |
Conditions studied
- Urinary Incontinence, Urge — all drugs for Urinary Incontinence, Urge →
- Fecal Incontinence — all drugs for Fecal Incontinence →
Sponsor
University of Alabama at Birmingham
Who can join
18 and older, female only, with Urinary Incontinence, Urge or Fecal Incontinence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational research study will examine whether a medication known as darifenacin (Enablex ®) used for urgency urinary incontinence (UUI) also helps to improve fecal incontinence symptoms. Darifenacin is FDA approved for UUI, but is not FDA approved for fecal incontinence or specifically for dual incontinence (treatment of urinary incontinence and fecal incontinence at the same time). If participants are eligible for this study, they will have had symptoms of bothersome urgency urinary incontinence and fecal incontinence, and have decided to try medication for urgency urinary incontinence. Darifenacin (Enablex ®) is an oral medication which relaxes the bladder muscle to help prevent urgency urinary leakage. It is commonly used to treat overactive bladder and urgency urinary leakage. There is some evidence that this medication may also help with fecal incontinence by slowing the gut and preventing loose stools. Investigators are planning to enroll approximately 30 patients who have both UUI and fecal incontinence and who choose medical treatment as a part of their standard care.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of darifenacin on fecal incontinence in women with double incontinence.
Kissane LM, Martin KD, Meyer I, Richter HE. · · 2021 · cited 5× · PMID 32542466 · DOI 10.1007/s00192-020-04369-3
Verify or expand the search:
- PubMed search for NCT03543566
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urinary Incontinence, Urge
Currently open trials in the same condition.
- NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
- NCT06754189 — Safety and Performance of UCon Patch Electrode · NA · recruiting
- NCT06091566 — Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfunction (BD) · NA · recruiting
- NCT05874375 — UCon Treatment of Overactive Bladder (OAB) in Males · NA · recruiting
- NCT05362292 — TReating Incontinence for Underlying Mental and Physical Health · Phase 4 · recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03543566 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 22 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03543566.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing